KUALA LUMPUR, May 30 (Bernama) -- LintonPharm Co Ltd, a China-based biopharmaceutical company, announced that preliminary results of Catumaxomab for advanced Gastric Cancer (GC) with peritoneal metastasis has been published online at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
Abstract Title：Global multi-center phase I trial of the intraperitoneal infusion of anti-EpCAM x anti-CD3 bispecific antibody catumaxomab for advanced gastric carcinoma with peritoneal metastasis.
The abstract is about the cohort A, stage I of the ongoing global phase Ⅲ trial that evaluates the safety and efficacy of Catumaxomab in advanced GC patients with peritoneal metastasis.
According to a statement, worldwide, GC is one of the most common cancers, contributing to more than one million cases per year and 5.6 per cent of all cancer diagnoses.
Approximately, 50 per cent of the advanced GC patients will develop peritoneal metastasis after radical resection, along with malignant ascites in most cases.
Furthermore, peritoneal metastasis is associated with poor prognosis and quality of life compared with metastasis to other organs. Peritoneal metastasis is treated with systemic therapies.
The estimated survival period for the patients who fail to respond to third-line therapy is limited to only 2.3-2.4 months according to multiple RCTs.
In its study, nine GC patients with peritoneal metastasis (33 per cent had failed third-line therapy) were treated with Catumaxomab, the median overall survival was 3.4 months, with remarkable ascites regression.
Catumaxomab as an T cell engaging immunotherapy has showed promising early efficacy signals. Catumaxomab was approved by the European Medicines Agency in 2009 for the treatment of malignant ascites.
LintonPharm Co Ltd is a clinical-stage, research-oriented biopharmaceutical company committed to developing innovative T cell engaging bispecific antibodies with the goal of turning malignant cancers into manageable and possibly curable diseases.
More details at www.lintonpharm.com.
-- BERNAMA
No comments:
Post a Comment